Baseline patient characteristics and clinical responses (n = 15)
| Patient . | Age, y . | Stage/subtype . | Prior therapy no./type . | Clinical response . | TTR, wk . | DOR, wk . | TTP, wk . |
|---|---|---|---|---|---|---|---|
| Single immunization procedure | |||||||
| 1 | 60 | IIB | 3/TS, RT, UVB | SD | n/a | n/a | 19.4 |
| 2 | 61 | IIB | 6/NM, UVB, PUVA + bex, bex, anti-CD4 | PR | 7.9 | 12.4 | 20.3 |
| 3 | 34 | IIB | 6/TS, TSEBT, NM, bex, bex + IFN, b-gel | SD | n/a | n/a | n/a (EOS week 10.6) |
| 4 | 61 | IB | 9/TS, UVB, PUVA, bex, NM, anti-CD4, RT, b-gel, forodesine | SD | n/a | n/a | n/a (EOS week 28.9) |
| 5 | 65 | IIB | 5/TS, TSEBT, NM, bex, b-gel | PR | 7.3 | 7.0 | n/a (EOS week 14.3) |
| 6 | 60 | IIB/LCT | 7/TS, TSEBT, NM, PUVA, b-gel, anti-CD4, RT | PD | n/a | n/a | 11.4 |
| 7 | 38 | IB | 2/NM + TS, UVB | SD | n/a | n/a | n/a (EOS week 17.0) |
| Dual immunization procedure | |||||||
| 8 | 69 | IIB/LCT | 8/TSEBT, IFN, TS, bex, chlorambucil, MTX, RT, gem, comb chemo | PD | n/a | n/a | 4.0 |
| 9 | 71 | IB | 3/TS, UVB, NM | PR | 12.0 | 6.1 | n/a (EOS week 18.1) |
| 10 | 47 | IIB/FMF | 5/TS, RT, bex, MTX, IFN | PD | n/a | n/a | 2.4 |
| 11 | 57 | IB/FMF | 3/UVB, TS, bex | PR | 11.1 | 6.0 | n/a (EOS week 17.1) |
| 12 | 38 | IIB/GMF | 3/RT, UVB, TS | PR | 7.1 | 37.0 | n/a (EOS week 44.1) |
| 13 | 55 | IIB | 2/TS, UVB | SD | n/a | n/a | n/a (EOS week 2; grade 3 injection-site reaction) |
| 14 | 46 | IB | 2/TS, NM | SD | n/a | n/a | 15.1 |
| 15 | 18 | IIB | 5/NM, TS, bex, UVB, RT | SD | n/a | n/a | n/a (EOS week 15.0) |
| Patient . | Age, y . | Stage/subtype . | Prior therapy no./type . | Clinical response . | TTR, wk . | DOR, wk . | TTP, wk . |
|---|---|---|---|---|---|---|---|
| Single immunization procedure | |||||||
| 1 | 60 | IIB | 3/TS, RT, UVB | SD | n/a | n/a | 19.4 |
| 2 | 61 | IIB | 6/NM, UVB, PUVA + bex, bex, anti-CD4 | PR | 7.9 | 12.4 | 20.3 |
| 3 | 34 | IIB | 6/TS, TSEBT, NM, bex, bex + IFN, b-gel | SD | n/a | n/a | n/a (EOS week 10.6) |
| 4 | 61 | IB | 9/TS, UVB, PUVA, bex, NM, anti-CD4, RT, b-gel, forodesine | SD | n/a | n/a | n/a (EOS week 28.9) |
| 5 | 65 | IIB | 5/TS, TSEBT, NM, bex, b-gel | PR | 7.3 | 7.0 | n/a (EOS week 14.3) |
| 6 | 60 | IIB/LCT | 7/TS, TSEBT, NM, PUVA, b-gel, anti-CD4, RT | PD | n/a | n/a | 11.4 |
| 7 | 38 | IB | 2/NM + TS, UVB | SD | n/a | n/a | n/a (EOS week 17.0) |
| Dual immunization procedure | |||||||
| 8 | 69 | IIB/LCT | 8/TSEBT, IFN, TS, bex, chlorambucil, MTX, RT, gem, comb chemo | PD | n/a | n/a | 4.0 |
| 9 | 71 | IB | 3/TS, UVB, NM | PR | 12.0 | 6.1 | n/a (EOS week 18.1) |
| 10 | 47 | IIB/FMF | 5/TS, RT, bex, MTX, IFN | PD | n/a | n/a | 2.4 |
| 11 | 57 | IB/FMF | 3/UVB, TS, bex | PR | 11.1 | 6.0 | n/a (EOS week 17.1) |
| 12 | 38 | IIB/GMF | 3/RT, UVB, TS | PR | 7.1 | 37.0 | n/a (EOS week 44.1) |
| 13 | 55 | IIB | 2/TS, UVB | SD | n/a | n/a | n/a (EOS week 2; grade 3 injection-site reaction) |
| 14 | 46 | IB | 2/TS, NM | SD | n/a | n/a | 15.1 |
| 15 | 18 | IIB | 5/NM, TS, bex, UVB, RT | SD | n/a | n/a | n/a (EOS week 15.0) |
FMF indicates folliculotropic MF; LCT, large cell transformation; GMF, granulomatous MF; TS, topical steroid; UVB, ultraviolet light B therapy; NM, topical nitrogen mustard/mechlorethamine; PUVA, ultraviolet light A with oral psoralen; bex, oral bexarotene; anti-CD4, fully human anti-CD4 monoclonal antibody; TSEBT, total skin electron beam therapy; b-gel, topical bexarotene gel; forodesine, purine nucleoside phosphorylase inhibitor; MTX, methotrexate; gem, gemcitabine; TTP time to progression; n/a, not applicable; EOS, end of study–withdrawal of consent to initiate MF therapy due to worsening symptoms without documented progressive disease; RT, radiation therapy; comb chemo, combination chemotherapy; and n/a, not applicable.